Kiadis Pharma is a clinical stage biopharmaceutical company
developing innovative and potentially life‑saving therapies for
patients with late stage blood cancers and related disorders in
need of a transplant, an area of significant unmet medical need.
ATIR™ is Kiadis Pharma’s lead product in development and enables partially
matched stem cells from family members (haploidentical donors) to be used
in reconstituting the immune system of blood cancer patients after a bone
marrow transplantation without eliciting severe or life threatening Graft-versus-Host-Disease (GvHD).
The Company is currently sponsoring a multi‑center Phase II
clinical trial for its lead product ATIR™ and is collaborating with renowned centers in Europe and North America.
October 30, 2014Kiadis Pharma’s lead product ATIR™ granted Orphan Drug Designation by EMA for the treatment of Acute Myeloid Leukemia
September 3, 2014Kiadis Pharma appoints Jeroen Rovers as its Chief Medical Officer
March 24, 2014Kiadis Pharma organizes a satellite symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation
January 29, 2014Kiadis Pharma initiates collaboration for personalized immunotherapies using ATIR™ with Technische Universität München
Click to download the Company Fact Sheet which provides a valuable insight into where Kiadis Pharma stands today. It summarizes what the Company's lead product ATIR™ is about, its market potential and the progress that is being made in clinical development.
Kiadis Pharma has recently been granted a U.S. patent regarding the Company’s lead product ATIR™, a cell-based treatment in development that enables partially matched stem cells from family members to be used in reconstituting the immune system of blood cancer patients.
Kiadis Pharma was previously granted broad patent protection in the U.S. for the full ATIR™ manufacturing process, the device and the therapeutic use of ATIR™, and the patent recently granted (United States Patent No. 8,802,082) has now extended this protection to an additional rhodamine derivative.
ATIR™ Phase I/II study completed
5‑year follow‑up of patients with high‑risk malignancies from Phase I/II clinical study confirms long‑term safety and efficacy of ATIR™ over a broad dose range.
Advanced Therapies Investor Day
November 13, 2014 - London, United Kingdom
American Society of Hematology (ASH) Annual Meeting
December 6-9, 2014 - San Francisco, USA
Phacilitate Cell & Gene Therapy Forum
January 26-28, 2015 - Washington DC, USA
European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting
March 22-25, 2015 - Istanbul, Turkey